Clinical trial NCT03608501: A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
Official title: An Open-Label, Single-Arm Phase II Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-Naive Multiple Myeloma Patients Non-Eligible for Autologous Stem-Cell Transplantation
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Multiple Myeloma
Keywords: Drug therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2018-08-01
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to determine the overall response rate (ORR) during induction therapy with the combination of ixazomib, thalidomide and low-dose dexamethasone in specific time points.

Detailed description: The drugs being tested in this study are a combination therapy of ixazomib, thalidomide and low-dose dexamethasone. This combination therapy is being tested to treat people who are newly diagnosed with multiple myeloma and non-eligible to autologous stem cell transplantation (ASCT). This study will assess the ORR during induction therapy in specific timepoints.

The study will enroll approximately 40 participants. All participants will receive:

Ixazomib citrate 4 mg + Thalidomide 100 mg and Dexamethasone 40 mg.

All participants will be asked to take their study medication at approximately the same time each day.

This multi-center trial will be conducted in Brazil. The overall time to participate in this study is approximately 5 years. Participants will make multiple visits to the clinic, and will be contacted by telephone or will make a final visit 30 days after receiving their last dose of drug or resolution of serious adverse event (SAE), whichever occurs later for a follow-up assessment.

Eligibility criteria: Inclusion Criteria:

1. Clonal bone marrow plasma cells \>=10% or biopsy-proven bony or extramedullary plasmacytoma and any one or more of the following myeloma defining events:

   * Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically:

     * Hypercalcaemia: serum calcium greater than (\>) 1 mg/dL higher than the upper limit of normal (ULN) or \>11 mg/dL;
     * Renal insufficiency: creatinine clearance \<40 milliliter (mL) per minute (as per validated equations) or serum creatinine \>2 mg/dL;
     * Anemia: haemoglobin value of \>20 gram per liter (g/L) below the lower limit of normal, or a haemoglobin value \<100 g/L;
     * Bone lesions: one or more osteolytic lesions on skeletal radiography, computed tomography (CT), or positron emission tomography (PET)-CT.
   * Any one or more of the following biomarkers of malignancy:

     * Clonal bone marrow plasma cell percentage \>=60%.
     * Involved: uninvolved serum free light chain ratio \>=100.
     * Greater than (\>) 1 focal lesions on magnetic resonance imaging (MRI) studies. Note: clonality should be established by showing kappa to lambda ratio (κ/λ)-light-chain restriction on flow cytometry, immunohistochemistry, or immunofluorescence. Bone marrow plasma cell percentage should preferably be estimated from a core biopsy specimen; in case of a disparity between the aspirate and core biopsy, the highest value should be used.
2. Ineligibility to autologous transplantation, as per investigator's discretion, regardless of age (the reason for such ineligibility should be recorded on the electronic case report form \[eCRF\]).
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
4. Ability to take concurrent aspirin daily (or enoxaparin subcutaneously daily), per published standard or institutional standard of care, as prophylactic anticoagulation.
5. Note: For participants with prior history of deep vein thrombosis (DVT), low molecular weight heparin (LMWH) is mandatory.
6. Left ventricular ejection fraction (LVEF) \>=50%.
7. Clinical laboratory values as specified below within 7 days before the first dose of study drug:

   * Absolute neutrophil count (ANC) \>=1,500 per cubic millimeter (/mm\^3), unless related to bone marrow infiltration by malignant plasma cells.
   * Hemoglobin \>=8.0 g/dL
   * Platelet count \>=75,000/mm\^3, unless related to bone marrow infiltration by malignant plasma cells (platelet transfusions to help participants meet eligibility criteria are not allowed).
   * Aspartate aminotransferase (AST) and alanine aminotransferase (AST) less than or equal to (\<=) 1.5 times the institutional ULN.
   * Bilirubin \<=1.5 mg/dL (or \<=2.5 mg/dL in case of Gilbert-Meulengracht syndrome).
   * Glomerular filtration rate \>=30 milliliter per minute per (mL/min/) 1.73 square meter (m\^2) according to the Modification of Diet in Renal Disease (MDRD) study abbreviated formula. If not on target, this evaluation may be repeated once after at least 24 hours.
   * Prothrombin time (PT) or activated partial thromboplastin time (aPTT) within normal limits.

Exclusion Criteria:

1. Presence of non-secretory or oligo-secretory myeloma, smoldering MM, monoclonal gammopathy of undetermined significance, plasma-cell leukemia, Waldenstrom's macroglobulinemia, primary amyloidosis, or polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome.
2. Central nervous system involvement by MM.
3. Prior radiation therapy involving an estimated \>=25% of the hematopoietically active bone marrow. Radiotherapy should not be given within 14 days before enrollment. In case of palliative radiotherapy for pain control and if the involved field is small, 7 days will be considered a sufficient interval between the radiation treatment and administration of the study drugs.
4. Treatment with any investigational products within 1 (one) year before the first dose of the study drug regimen.
5. Presence of peripheral neuropathy of grade 1 with pain or grade 2 or higher.
6. Previous or concurrent history of malignancies other than MM except for curatively treated cervical carcinoma in situ, non-melanoma skin cancer, superficial bladder cancer (Ta \[non-invasive tumor\], Tis \[carcinoma in situ\] and T1 \[tumor invades lamina propria\]), or localized prostate cancer.
7. With evidence or history of bleeding diathesis. Any hemorrhage or bleeding event \>=common terminology criteria for adverse events (CTCAE) Grade 3 within 4 weeks of start of study medication.
8. Major surgery within 14 days before randomization.
9. Non-healing wound or ulcer.
10. Seizure disorder requiring medication.
11. Systemic treatment with strong cytochrome P-450 3A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort from Day-14 of cycle 1 until the safety follow-up.
12. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before the start of study medication.

Primary outcomes:
measure: ORR During Induction
timeFrame: Upon ORR assessment during specific timepoints for all participants completing or withdrawn prematurely from the induction phase (Baseline up to approximately 9 month [Cycle 9])
Secondary outcomes:
measure: Progression-free Survival (PFS)
timeFrame: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 2 years])
measure: ORR During Maintenance
timeFrame: Upon ORR assessment during specific time points for all participants completing or withdrawn prematurely from maintenance phase (Baseline up to approximately 2 years)
measure: Overall Survival (OS)
timeFrame: Upon study termination (Baseline up to approximately 5 years)
measure: Time to Response During Induction
timeFrame: End of induction phase (Baseline up to approximately 9 months [Cycle 9])
Other outcomes:
Locations:
city: Salvador
country: Brazil
facility: CEHON Centro de Hematologia e Oncologia da Bahia
state: BA
city: Rio de Janeiro
country: Brazil
facility: Instituto COI de Educacao e Pesquisa
state: RJ
city: Porto Alegre
country: Brazil
facility: Hospital de Clinicas de Porto Alegre
state: RS
city: Campinas
country: Brazil
facility: Universidade Estadual de Campinas UNICAMP - HEMOCENTRO
state: SP
city: Sao Paulo
country: Brazil
facility: Clinica Medica Sao Germano S/S Ltda.
state: SP
city: Sao Paulo
country: Brazil
facility: Hospital das Clinicas da Faculdade de Medicina da USP
state: SP
Study officials:
affiliation: Takeda
name: Medical Director
role: STUDY_DIRECTOR
References: